| 1 |
34515877 | Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. | 2022 Feb |
1 |
| 2 |
35170228 | Effect of food on capsule and granule formulations of selumetinib. | 2022 Apr |
1 |
| 3 |
35171389 | Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. | 2022 Feb 16 |
4 |
| 4 |
35210278 | ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. | 2022 Mar |
1 |
| 5 |
35246426 | Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. | 2022 Mar 4 |
2 |
| 6 |
35250023 | Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. | 2022 Mar 7 |
2 |
| 7 |
35406545 | Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas. | 2022 Mar 31 |
1 |
| 8 |
35410754 | A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib. | 2022 Apr |
2 |
| 9 |
33273059 | AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. | 2021 Feb |
3 |
| 10 |
33405090 | Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. | 2021 Jun |
2 |
| 11 |
33536190 | Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. | 2021 Apr |
1 |
| 12 |
33631016 | A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. | 2021 Oct 1 |
1 |
| 13 |
33683166 | Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. | 2021 May |
1 |
| 14 |
33808483 | Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico. | 2021 Mar 30 |
1 |
| 15 |
33903938 | Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. | 2021 Aug |
2 |
| 16 |
33978635 | Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. | 2021 Jan-Dec |
1 |
| 17 |
34196005 | Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. | 2021 Nov |
2 |
| 18 |
34680330 | Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. | 2021 Oct 15 |
1 |
| 19 |
34831012 | MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells. | 2021 Nov 22 |
1 |
| 20 |
32108293 | Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. | 2020 Apr |
3 |
| 21 |
32504375 | Selumetinib: First Approval. | 2020 Jun |
3 |
| 22 |
32629964 | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. | 2020 Jun 30 |
2 |
| 23 |
32880495 | Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. | 2020 Nov |
1 |
| 24 |
33099927 | Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells. | 2020 Jul-Aug |
1 |
| 25 |
30317534 | Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. | 2019 Jun |
3 |
| 26 |
30972766 | MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. | 2019 Sep |
1 |
| 27 |
31151904 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. | 2019 Jul |
1 |
| 28 |
31200828 | Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. | 2019 Jul |
1 |
| 29 |
31409052 | Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. | 2019 Aug 12 |
1 |
| 30 |
28833380 | Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. | 2018 Jan |
1 |
| 31 |
28986121 | A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses. | 2018 Jan |
1 |
| 32 |
29216787 | MEK inhibitors under development for treatment of non-small-cell lung cancer. | 2018 Jan |
1 |
| 33 |
29526823 | Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. | 2018 Jun |
1 |
| 34 |
29528792 | Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). | 2018 Apr 20 |
3 |
| 35 |
29737325 | The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. | 2018 May 8 |
2 |
| 36 |
29915160 | The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. | 2018 Aug 15 |
1 |
| 37 |
30414267 | Effects of Erythromycin on the Proliferation and Apoptosis of Cultured Nasal Polyp-Derived Cells and the Extracellular Signal-Regulated Kinase (ERK)/Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway. | 2018 Nov 10 |
1 |
| 38 |
27889832 | Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. | 2017 Feb |
1 |
| 39 |
28019010 | Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects. | 2017 May |
1 |
| 40 |
28212559 | The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo. | 2017 Mar 28 |
2 |
| 41 |
28264648 | A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. | 2017 Mar 6 |
3 |
| 42 |
28283692 | Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. | 2017 Jun |
2 |
| 43 |
28326681 | Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. | 2017 May |
2 |
| 44 |
28385507 | Discovery of a cobalt complex with high MEK1 binding affinity. | 2017 May 15 |
1 |
| 45 |
28424891 | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. | 2017 Oct |
3 |
| 46 |
28791489 | Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway. | 2017 Nov |
1 |
| 47 |
28819429 | MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. | 2017 |
3 |
| 48 |
28849200 | Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. | 2017 Oct |
3 |
| 49 |
28931905 | Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. | 2017 Sep 20 |
2 |
| 50 |
26446942 | A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. | 2016 Mar 1 |
3 |